CN108289903B - 与检验点抑制剂联合使用2-脱氧-2-氟-l-岩藻糖的癌症治疗 - Google Patents

与检验点抑制剂联合使用2-脱氧-2-氟-l-岩藻糖的癌症治疗 Download PDF

Info

Publication number
CN108289903B
CN108289903B CN201680071076.0A CN201680071076A CN108289903B CN 108289903 B CN108289903 B CN 108289903B CN 201680071076 A CN201680071076 A CN 201680071076A CN 108289903 B CN108289903 B CN 108289903B
Authority
CN
China
Prior art keywords
cancer
cells
fucose
deoxy
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680071076.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108289903A (zh
Inventor
S·加尔达
C-L·朗
P·森特
N·奥克利
J·菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of CN108289903A publication Critical patent/CN108289903A/zh
Application granted granted Critical
Publication of CN108289903B publication Critical patent/CN108289903B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680071076.0A 2015-12-04 2016-12-02 与检验点抑制剂联合使用2-脱氧-2-氟-l-岩藻糖的癌症治疗 Expired - Fee Related CN108289903B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US62/263,228 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US62/308,583 2016-03-15
US201662321857P 2016-04-13 2016-04-13
US62/321,857 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (2)

Publication Number Publication Date
CN108289903A CN108289903A (zh) 2018-07-17
CN108289903B true CN108289903B (zh) 2021-08-03

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680071076.0A Expired - Fee Related CN108289903B (zh) 2015-12-04 2016-12-02 与检验点抑制剂联合使用2-脱氧-2-氟-l-岩藻糖的癌症治疗

Country Status (13)

Country Link
US (1) US20180353524A1 (enExample)
EP (1) EP3383404A4 (enExample)
JP (1) JP6906520B2 (enExample)
KR (1) KR20180086233A (enExample)
CN (1) CN108289903B (enExample)
AU (1) AU2016362993A1 (enExample)
BR (1) BR112018011261A2 (enExample)
CA (1) CA3005997A1 (enExample)
EA (1) EA201891340A1 (enExample)
IL (1) IL259479B (enExample)
MX (1) MX385283B (enExample)
SG (2) SG11201804263PA (enExample)
WO (1) WO2017096274A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2608796B1 (en) 2010-08-05 2018-11-21 Seattle Genetics, Inc. Inhibition of protein fucosylation in vivo using fucose analogs
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
MX2019014584A (es) * 2017-06-07 2020-02-07 Seattle Genetics Inc Celulas t con fucosilacion de superficie reducida y metodos para preparar y usar las mismas.
WO2019075449A1 (en) * 2017-10-13 2019-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
WO2020132096A1 (en) * 2018-12-19 2020-06-25 Seattle Genetics, Inc. Controlled fucosylation of antibodies
US20220305038A1 (en) * 2019-08-16 2022-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US20240197761A1 (en) * 2021-04-16 2024-06-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
US20240238318A1 (en) * 2021-05-06 2024-07-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料
WO2024077106A2 (en) * 2022-10-04 2024-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402525A (zh) * 2010-08-05 2013-11-20 西雅图基因公司 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402525A (zh) * 2010-08-05 2013-11-20 西雅图基因公司 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Abstract 2890: Mechanistic evaluation of the anti-tumor activities of 2-fluorofucose alone and in combination with anti-idiotype vaccination;Nicole M. Okeley等;《Experimental and Molecular Therapeutics》;20141031;第74卷(第19期);摘要 *
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma;J. Larkin等;《The New England Journal of Medicine》;20150531;第1-12页 *
Human Cancer Antigen Globo H Is a Cell-Surface Ligand for Human Ribonuclease 1;Chelcie H. Eller等;《ACS Cent.Sci.》;20150713;第1卷;第181-190页 *

Also Published As

Publication number Publication date
EA201891340A1 (ru) 2018-11-30
MX385283B (es) 2025-03-18
BR112018011261A2 (pt) 2018-11-21
SG11201804263PA (en) 2018-06-28
SG10202005298RA (en) 2020-07-29
CN108289903A (zh) 2018-07-17
EP3383404A4 (en) 2019-07-31
MX2018006674A (es) 2018-11-09
KR20180086233A (ko) 2018-07-30
JP6906520B2 (ja) 2021-07-21
JP2019501145A (ja) 2019-01-17
IL259479B (en) 2022-03-01
CA3005997A1 (en) 2017-06-08
AU2016362993A1 (en) 2018-07-12
WO2017096274A1 (en) 2017-06-08
IL259479A (en) 2018-07-31
US20180353524A1 (en) 2018-12-13
EP3383404A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
CN108289903B (zh) 与检验点抑制剂联合使用2-脱氧-2-氟-l-岩藻糖的癌症治疗
US20230414540A1 (en) Combination of immunotherapy with local chemotherapy for the treatment of malignancies
US20250213689A1 (en) Immunogenic composition for the treatment of cancer
BR112021002826A2 (pt) construtos de receptor de célula t e usos dos mesmos
JP2020164539A (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
WO2019241730A2 (en) Increasing immune activity through modulation of postcellular signaling factors
JP7233220B2 (ja) Ｈｄａｃ阻害剤とｂｅｔ阻害剤の使用方法及びその薬学的組み合わせ
CA2980730A1 (en) Tolerogenic nanoparticles for treating diabetes mellitus
JP2022512161A (ja) 免疫療法のための組成物及び方法
CN113316449A (zh) 胍那苄作为免疫疗法的佐剂
WO2022265864A9 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
Wang et al. A novel role of the scaffolding protein JLP in tuning CD40-induced activation of dendritic cells
EP3630126A1 (en) Ceramide nanoliposomes, compositions and methods of using for immunotherapy
JP2017526702A (ja) ＰＰＡＲ−γアゴニストを投与する段階を含む、癌を治療する方法
WO2024163605A1 (en) Use of glutamine for the treatment of cancer and for enhancing the efficacy of an immunotherapy
EP3750988A1 (en) Improved alpha beta t processed cell production method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210803

CF01 Termination of patent right due to non-payment of annual fee